
Journal of Medicinal Chemistry p. 413 - 419 (1998)
Update date:2022-07-30
Topics:
Sullivan, Robert W.
Bigam, Colin G.
Erdman, Paul E.
Palanki, Moorthy S. S.
Anderson, David W.
Goldman, Mark E.
Ransone, Lynn J.
Suto, Mark J.
Described is the identification of a novel series of compounds that blocks the activation of two key transcription factors, AP-1 and NF-κB. These transcription factors regulate the expression of several critical proinflammatory proteins and cytokines and represent attractive targets for drug discovery. Through the use of high throughput screening and solution- phase parallel synthesis, inhibitors of both NF-κB and AP-1 were identified. In subsequent testing, these compounds were also shown to block both IL-2 and IL-8 levels in the same cells. One of the most potent compounds in this series, 28, was active in several animal models of inflammation and immunosuppression, thus validating the importance of AP-1 and NF-κB as potential therapeutic targets. The synthesis and preliminary structure- activity relationships of these compounds is addressed.
View MoreZHEJIANG CHEMICAL INDUSTRY INSTITUTE TECHNOLOGY CO.,LTD(expird)
Contact:86-575-82730298
Address:shangyu
Shanghai He Yang International Trading Co., Ltd.
Contact:+86-21-52043598
Address:Room 816, Blag.5, No.58 Huachi Road
Hunan Zhongqi Pharmaceutical Co., Ltd
website:http://www.hnzqzy.com
Contact:0730-8722288 13807308622
Address:Wanjiafan Road ,Yueyang Economic And Technological Development Zone ,Hunan,PRC
Hubei Xinghuo Chemical Co., Ltd.,
Contact:13925817279 13907299441
Address:Xinghuo Fine Chemistry Industrial Park, Xiaochang County, Hubei Province, China
Hangzhou Neway Chemicals Co., Ltd.
Contact:+86-571-85095566
Address:Room 803, Qinglian Bldg, No 139 Qingchun Road, Hangzhou, Zhejiang China
Doi:10.3390/molecules25204718
(2020)Doi:10.1021/ja020012f
(2002)Doi:10.1002/adsc.201400190
(2014)Doi:10.1021/j100162a039
(1991)Doi:10.1016/S0040-4039(00)01460-X
(2000)Doi:10.1515/znb-2001-0817
(2001)